Cancer Cachexia Market Set to Witness Significant Growth Through 2035 – BIS Research

What Is Cancer Cachexia? 

Cancer cachexia is a complex metabolic syndrome characterized by involuntary weight loss, muscle wasting, and systemic inflammation in cancer patients. It significantly reduces treatment tolerance, quality of life, and survival rates, often occurring in advanced cancer stages and requiring a combination of nutritional, pharmacological, and exercise-based interventions. 

What Is the Market Outlook? 

Technology Growth: 

The treatment landscape is shifting toward multi-targeted therapies combining anti-inflammatory agents, appetite stimulants, and metabolic modulators, alongside nutritional and exercise interventions. 

Regional Drivers: 

• North America: Strong market share driven by advanced supportive care frameworks, established palliative care networks, and accelerated drug approvals. 
• Europe: Growth supported by rare disease frameworks, oncology palliative care integration, and government-backed nutrition programs. 
• Asia-Pacific: Rapid expansion due to increasing oncology service capacity, patient advocacy, and regional clinical trial participation. 

Commercialization Push: 

Strategic collaborations between pharmaceutical companies, oncology centers, and nutrition specialists are accelerating the development and rollout of novel therapies targeting cachexia’s inflammatory and metabolic pathways. 

How Fast Is the Market Growing? 

The cancer cachexia market is anticipated to grow at a steady CAGR through 2035, with targeted metabolic therapy segments outpacing traditional appetite stimulants. Approvals of agents such as ghrelin receptor agonists and selective androgen receptor modulators are expected to improve patient outcomes and expand treatment adoption. 

How Will This Report Help You? 

Planning to Enter the Market? 

• Analyze therapy adoption rates across oncology indications and regions, with insights into patient population estimates and clinical practice patterns. 

Analyzing the Competitive Landscape? 

• Evaluate pharma pipelines, orphan drug designations, and licensing deals shaping the future of cancer cachexia treatment. 

Seeking R&D Insights? 

• Track developments in anti-inflammatory therapeutics, ghrelin mimetics, anabolic agents, and combination supportive care regimens. 

Interested in Regional Market Trends? 

• Review country-specific reimbursement policies, integration of cachexia care into oncology pathways, and clinical trial density. 

Download the Full TOC or Book a Preview     

What’s Driving Demand, Opportunities, and Barriers? 

Demand Drivers: 

• Rising prevalence of advanced cancer stages with high cachexia incidence 
• Increased awareness among oncologists of cachexia’s impact on survival 
• Development of targeted metabolic therapies and biologics 

Opportunities: 

• Expansion of personalized supportive care models 
• Greater integration of digital health tools for patient monitoring 
• Emerging market access for novel cachexia treatments 

Challenges: 

• Limited clinical guidelines and physician familiarity in early intervention 
• Small patient trial populations slowing evidence generation 
• Regulatory hurdles for multi-mechanism combination therapies 

Market Segmentation 

by Therapy Type 

• Pharmacological Therapies 

        o Corticosteroids 

        o NSAIDs 

        o Anamorelin 

        o Progestin 

        o Cannabinoids 

        o Combination Drugs 

        o Others 

• Non-Pharmacological Therapies 

        o Nutritional Support 

        o Exercise Therapy 

by Stage of Cachexia 

•    Pre-Cachexia 

•    Cachexia 

•    Refractory Cachexia 

by Region 

•    North America 

•    Europe  

•    Asia-Pacific 

Key Players 

•      Helsinn Group 

•      Fresenius Kabi 

•      Hikma Pharmaceuticals PLC 

•      Pfizer 

•      Zydus Group 

•      Actimed Therapeutics 

•      NGM Biopharmaceuticals 

•      Cannabics Pharmaceuticals 

Strategic Developments: 

• Orphan drug approvals for cachexia-specific agents in select oncology subtypes 
• Partnerships between oncology and nutrition-focused companies 
• Launch of global registries to monitor real-world treatment outcomes 

Download the complete TOC now! 

Case Study: 

Ongoing Phase III trials for ghrelin receptor agonists in lung and pancreatic cancer patients with cachexia have shown promising improvements in lean body mass and appetite, indicating a shift toward targeted metabolic intervention over purely nutritional support. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Non-Metastatic Prostate Cancer Market 

Testicular Cancer Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc